SCHEMBL18148044

SCHEMBL18148044

Cn1cnc2c(F)c(C=CC(=O)O)c(NS(=O)(=O)c3ccc[nH]3)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 2/20 0.34
POLB P06746 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 1/20 0.34
AKT1 P31749 2/20 0.33
CNKSR1 Q969H4 2/20 0.33
RECQL P46063 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
PTGER3 P43115 4/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KEAP1 Q14145 1/20 0.32
NFE2L2 Q16236 1/20 0.32
IDH1 O75874 1/20 0.31
KAT6A Q92794 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18148041 1.00 LMNA (0.37) LMNAMEN1KMT2ATDP1POLB
SCHEMBL18148033 0.91 HDAC1 (0.36) LMNAMEN1KMT2ACNKSR1RECQL
SCHEMBL18148036 0.91 HDAC1 (0.36) LMNAMEN1KMT2ACNKSR1RECQL
SCHEMBL18163759 0.87 CNKSR1 (0.38) LMNAMEN1KMT2APOLBAKT1
SCHEMBL18147963 0.87 PIK3CA (0.40) LMNATDP1POLBL3MBTL1CNKSR1
SCHEMBL18148080 0.82 CNKSR1 (0.51) MEN1KMT2AAKT1CNKSR1HDAC1
SCHEMBL18148082 0.82 CNKSR1 (0.51) MEN1KMT2AAKT1CNKSR1HDAC1
SCHEMBL18148024 0.78 LMNA (0.35) LMNAMEN1KMT2AKDM4ERECQL
SCHEMBL18148199 0.78 ACLY (0.38) LMNAMEN1KMT2ARECQLSMN1; SMN2
SCHEMBL18147950 0.76 LMNA (0.36) LMNAMEN1KMT2APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2019-03-12 US disclosed
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 PHUSIS THERAPEUTICS, INC. (US) 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227356-B2 Compounds, compositions and methods for inhibiting CNKSR1 CNKSR1, CAMKK1, CNR1 LMNA 1703/4885MEN1 2360/4885KMT2A 2356/4885
US-20160304533-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING CNKSR1 CNKSR1, CAMKK1, CNR1 LMNA 1703/4885MEN1 2360/4885KMT2A 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.